Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
BioNxt Solutions seeks exclusive licensing for its oral thin film treatment in Eurasian and European markets, targeting high-MS regions.
BioNxt Solutions Inc. has signed a non-binding letter of intent to explore exclusive licensing for its sublingual cladribine oral thin film in one or more Eurasian Patent Organization member states, following patent grants in both the Eurasian region and Europe.
The EAPO patent, effective November 2025, covers eight countries with over 200 million people and expires in 2043.
The EPO granted a related patent on March 11, 2026, potentially covering up to 39 European countries through 2043.
The 60-day negotiation period focuses on a potential deal involving upfront payments, royalties, and collaboration on regulatory, manufacturing, and commercialization efforts.
The company is targeting markets with high rates of neurological and autoimmune conditions like Multiple Sclerosis, affecting about 2.9 million people globally.
BioNxt Solutions busca licencia exclusiva para su tratamiento de película delgada oral en los mercados euroasiático y europeo, dirigido a regiones con alto índice de EM.